MotherToBaby

Medications and More during pregnancy and breastfeeding

Search

866.626.6847

Miglustat (Zavesca®)

Selected References:

  • Amory JK, et al. 2007. Miglustat has no apparent effect on spermatogenesis in normal men. Hum Reprod; 22(3):702-707.  
  • Bone W, et al. 2007. The sensitivity of murine spermiogenesis to miglustat is a quantitative trait: a pharmacogenetic study. Reprod Biol Endocrinol; 5:1.  
  • Granovsky-Grisaru, S et al. 2011. The management of pregnancy in Gaucher disease. Thromb Haemost, 156:3-8. 
  • Hollak, C et al. 2009. Miglustat (Zavesca®) in type I Gaucher disease: 5-year results of a post-authorisation safety surveillance programme. Pharmacoepidemiol Drug Saf; 18:770-777. 
  • Miglustat (Zavesca®) Product Label. 2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021348s010lbl.pdf 
  • Suganuma R, et al. 2005. Alkylated imino sugars, reversible male infertility-inducing agents, do not affect the genetic integrity of male mouse germ cells during short-term treatment despite induction of sperm deformities. Biol Reprod; 72(4):805-813.  

This website is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling $6,000,000 with zero percentage financed with non-governmental sources. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, HRSA, HHS, or the U.S. Government.